Company intelligence / Profile preview

AlphaVax, Inc.

Durham, North Carolina, United Statesalphavax.com ↗

Ownership: Private
Employees: ~70
Development stage: Phase 2

Overview

Four alphavaccine candidates (targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1) have been evaluated in five Phase 1 clinical trials. Results from their first trial evaluating CEA alphavaccine in patients with Stage IV colon cancer showed the vector technology was able to "break self-tolerance" with a reported trend for enhanced survival in patients with CEA-specific T cell responses. The company has completed clinical trials in breast cancer and gastrointestinal cancers (in Stage III patients).

Therapeutic areas: OncologyInfectious Diseases
Modalities: RNA vaccinesself-amplifying RNA vaccines (saRNA)alphavaccine vector technology
Industry: Biotech

Drug pipeline

24 assets

Influenza alphavaccine

Approved

23 more assets in the full pipeline.

Request access →

Partnerships

Novartis Vaccines and Diagnostics, Inc. (for CMV)US government agenciesDepartment of Defense

Beyond the preview

Go deeper on AlphaVax, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlphaVax, Inc..

Explore the full profile